Siinä vähän lisää tietoa kyseisten lääkkeiden haitoista:
Raghu Chivukula, MD, PhD, a physician-scientist in the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital, explains what is currently known about chloroquine and its us
advances.massgeneral.org
"
Chivukula: Reservations to the enthusiasm for CQ/HCQ use fall into two major categories:
The first is passive: these drugs might simply be ineffective, sapping attention and resources from alternate treatments or trials and limiting supplies for patients who require HCQ for control of rheumatologic disease. There are legitimate reasons to be skeptical about possible benefits of these drugs in clinical settings given that clinical trials in other viral infections have been less than promising. Chloroquine
failed to prevent influenza infection in a clinical trial and, if anything,
increased viral load in an HIV trial. In COVID-19 specifically, a
small trial recently randomized 30 patients to HCQ or placebo and found no significant difference in clinical endpoints, though these were generally mildly affected patients.
The second is active: the possibility of harm associated with administering these agents, particularly to the critically ill. Concerningly, at least one group reported
increased influenza replication in vitro in the presence of CQ and another found that CQ
increased viremia in cynomolgus macaques infected with Chikungunya virus.
Hydroxychloroquine also has significant toxicities, particularly in the heart where it can increase the QT interval (especially a concern if co-administered with macrolides) and in the eye where it can cause an irreversible retinopathy (caused by its lysosomal accumulation). Therefore, until larger randomized trial data is available, there remains equipoise about the role for these drugs in COVID-19 patients despite their preclinical promise. "
www.the-sun.com
